Seinda Corporation

Seinda Corporation is dedicated to advancing global eye health through scientific innovation and a patient-centered approach. As the parent company of Seinda Pharmaceutical Corp. and Seinda Biomedical Corp., we are committed to developing breakthrough therapeutics and precision diagnostics for ocular diseases with unmet needs. Seinda Pharmaceutical is a clinical-stage, science-driven company focused on pioneering new treatments for dry eye disease (DED) and other ocular conditions. Our lead candidate, SY-201, a novel small peptide therapeutic, has demonstrated proof-of-concept in a U.S. Phase 2 clinical trial and is now progressing into Phase 3 trials in both the U.S. and China. Seinda Biomedical, founded in 2015, specializes in tear-based biomarker point-of-care tests that enable precision eye care. Through our proprietary i-ImmunDx™ platform, we have developed highly sensitive, accurate, and user-friendly diagnostic tools—including the LTa3-POC, IgE-POC, MMP9-POC, and IL6-POC tests—designed to support better patient stratification, disease severity assessment, and treatment selection in DED. At Seinda, we believe that innovation and collaboration can transform the future of ocular health. For mor information, please email info@seindabio.com or check out our website at www.seindabio.com.